130 related articles for article (PubMed ID: 28935649)
1. Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.
van den Hout MFCM; Koster BD; Sluijter BJR; Molenkamp BG; van de Ven R; van den Eertwegh AJM; Scheper RJ; van Leeuwen PAM; van den Tol MP; de Gruijl TD
Cancer Immunol Res; 2017 Nov; 5(11):969-977. PubMed ID: 28935649
[TBL] [Abstract][Full Text] [Related]
2. Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.
van Pul KM; Vuylsteke RJCLM; van de Ven R; Te Velde EA; Rutgers EJT; van den Tol PM; Stockmann HBAC; de Gruijl TD
J Immunother Cancer; 2019 May; 7(1):133. PubMed ID: 31118093
[TBL] [Abstract][Full Text] [Related]
3. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
[TBL] [Abstract][Full Text] [Related]
5. T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
Di Gennaro P; Gerlini G; Caporale R; Sestini S; Brandani P; Urso C; Pimpinelli N; Borgognoni L
Cancer Lett; 2018 Mar; 417():124-130. PubMed ID: 29306022
[TBL] [Abstract][Full Text] [Related]
6. Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma.
Tucci M; Stucci LS; Mannavola F; Passarelli A; D'Oronzo S; Lospalluti L; Giudice G; Silvestris F
Clin Transl Oncol; 2019 Jul; 21(7):845-854. PubMed ID: 30470990
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
[TBL] [Abstract][Full Text] [Related]
8. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
[TBL] [Abstract][Full Text] [Related]
9. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
10. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
Sluijter BJ; van den Hout MF; Koster BD; van Leeuwen PA; Schneiders FL; van de Ven R; Molenkamp BG; Vosslamber S; Verweij CL; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Res; 2015 May; 3(5):495-505. PubMed ID: 25633713
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node status affects long-term survival in patients with intermediate-thickness melanoma.
G Lben K; Berberoğlu U; Altınyollar H; Kınaş V; Turanlı S
J Cancer Res Ther; 2016; 12(2):840-4. PubMed ID: 27461661
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation.
van Pul KM; Vuylsteke RJ; Bril H; Stockmann HB; de Gruijl TD
J Immunol Methods; 2012 Jan; 375(1-2):189-95. PubMed ID: 22062586
[TBL] [Abstract][Full Text] [Related]
13. Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
Lino-Silva LS; Castillo-Medina AL; Salcedo-Hernández RA; García-Pérez L
Melanoma Res; 2017 Apr; 27(2):116-120. PubMed ID: 28030434
[TBL] [Abstract][Full Text] [Related]
14. Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients.
Gambichler T; Scholl L; Bechara FG; Stockfleth E; Stücker M
Eur J Surg Oncol; 2016 Sep; 42(9):1420-6. PubMed ID: 27160354
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.
Vermi W; Bonecchi R; Facchetti F; Bianchi D; Sozzani S; Festa S; Berenzi A; Cella M; Colonna M
J Pathol; 2003 Jun; 200(2):255-68. PubMed ID: 12754747
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.
Messaoudene M; Périer A; Fregni G; Neves E; Zitvogel L; Cremer I; Chanal J; Sastre-Garau X; Deschamps L; Marinho E; Larousserie F; Maubec E; Avril MF; Caignard A
PLoS One; 2015; 10(7):e0133363. PubMed ID: 26218530
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
18. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
19. The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.
Oosterhoff D; Sluijter BJ; Hangalapura BN; de Gruijl TD
Curr Top Microbiol Immunol; 2012; 351():181-220. PubMed ID: 21681685
[TBL] [Abstract][Full Text] [Related]
20. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
